Close Menu

MD Anderson

The trial will assess the safety and preliminary efficacy of ART0380, which Artios Pharma in-licensed from MD Anderson and ShangPharma Innovation in 2019.

The research and development partnership will focus on advancing Mirati's KRAS G12C and KRAS G12D inhibitors as treatments for solid cancers.

Treating patients with their own lymphocytes has been tricky to define as a product from the commercial perspective, but a forthcoming approval may change that.  

The transcription-based subtypes could differentiate which SCLC patients respond to treatments, such as immune checkpoint inhibitors and PARP inhibitors.

The Phase I trial will assess BBP-398's safety and anti-tumor activity in cancers with MAPK signaling pathway genetic mutations, including mutations in RAS genes.

Researchers have identified unique features associated with the degree to which LBCL patients respond to and experience toxicity with Yescarta.

TargetCancer is activating two enrollment sites and setting up a remote consenting process so patients with rare cancers can be seen at local community hospitals.

The alliance will join Sanofi's oncology pipeline with MD Anderson's premier clinical trials infrastructure to identify new biomarkers and streamline patient selection.

A study found that patients with a mutation in ARID1A and expression of immune cytokine CXCL13 had better overall survival on immune checkpoint inhibitors.

The collaboration will allow oncologists a streamlined view of the treatments and trials available to patients based on their genomic profile.